lilly
NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE
December 10, 2024Mounjaro, NICE, lilly, weight-loss
BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute for Health and Care Excellence …
Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy
April 19, 2021Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news
The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …
Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial
March 17, 2021Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis
Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …
University of Glasgow and Lilly sign £4.6m immunological disease partnership
February 15, 2021Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg
The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …
Top Ten most popular articles on Pharmafile.com this week
July 31, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Roche, UK government, Vaccine, lilly, pharma, top 10
Another week dominated by COVID-19. Among our most popular stories this week, Celltrion’s infliximab biosimilar Remsima has scored approval for …
Lilly promises $850 million investment in message to White House
March 27, 2017Manufacturing and Production, Sales and Marketing Eli Lilly, President trump, lilly
Eli Lilly’s latest press release indicated that it would be spending $850 million in developing its worldwide US operations, particularly …
Lilly posts impressive psoriasis results in comparison study
March 6, 2017Research and Development, Sales and Marketing J&J, JJ, Stelara, Taltz, lilly
Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. …
Lilly three strikes in three years not out in Teva patent challenge
January 13, 2017Medical Communications, Sales and Marketing Eli Lilly, Teva, generics, lilly, patent
Eli Lilly has successfully won a major patent case against Teva Pharmaceuticals, with the case being decided at the US …
MSD and Lilly announce immuno-oncology collaboration
January 11, 2017Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly
MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …
AZ and Lilly come together to battle Alzheimer’s
December 9, 2016Research and Development, Sales and Marketing AZ, lilly
Pharma titans Eli Lilly and AstraZeneca have announced they are to join forces to co-develop a potential Alzheimer’s treatment, currently …
FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca
August 22, 2016Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III
AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …
Lilly showcases positive late-stage data in diabetes treatments
June 13, 2016Research and Development, Sales and Marketing diabetes, lilly
Eli Lilly (NYSE: LLY) has presented data on their diabetes drugs in late-stage trials at the 76th American Diabetes Association …
Trial data shows promise for Lilly/MSD combo regimen in lung cancer
June 6, 2016Research and Development, Sales and Marketing MSD, Merck, collaboration, immuno-oncology, lilly, lung cancer, non-small cell, parternship
Eli Lilly (NYSE: LLY) has presented data at the American Society of Clinical Oncology (ASCO) annual congress showcasing its collaborations …
FDA approves Lilly/Boehringer Ingelheim type-2 diabetes drug
June 1, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, diabetes, jentadueto, jentadueto xr, lilly, partnership, type 2, type-2
The US Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended release) tablets for the …
Eli Lilly showcases emerging pipeline to investors
May 25, 2016Research and Development Eli Lilly, investors, lilly, pipeline, research and development
Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting its potential to launch 20 …
Latest content
FibroFind appoints Lee Borthwick as CEO
